Smoking and non-alcoholic steatohepatitis (NASH): The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial

Journal of Hepatology

Volumn 57, Issue 2, 2012, Pages 476-

  Katsiki, Niki ^a   Athyros, Vasilios G ^b   Karagiannis, Asterios ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DISEASE DURATION; DRUG SAFETY; HUMAN; LETTER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; SMOKING;

EID: 84863987606     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.013     Document Type: Letter

References (3)

1. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, and K. Kargiotis GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 376 2010 1916 1922
2. M. Babu, and N. Paul Smoking and NASH: a hidden message from the GREACE trial J Hepatol 56 2012 300 301
3. C.O. Zein, and A.J. McCullough Reply to: smoking and NASH: a hidden message from the GREACE trial J Hepatol 56 2012 301